MedPath

Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension

Phase 3
Completed
Conditions
Essential Hypertension
Registration Number
NCT00139698
Lead Sponsor
Pfizer
Brief Summary

Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
410
Inclusion Criteria
  • Subject has mild to moderate hypertension
Exclusion Criteria
  • History of secondary hypertension

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Efficacy of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
Secondary Outcome Measures
NameTimeMethod
Safety and tolerability of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Trial Locations

Locations (1)

Pfizer Investigational Site

© Copyright 2025. All Rights Reserved by MedPath